Clinical News

UEG Elections 2016

Friday, 08 April 2016 09:31

The UEG has given notice that the following positions will be elected during UEG Week Vienna 2016:

  • Chair of the Scientific Committee
  • Chair of the Public Affairs Committee
  • Two Members on the National Societies Committee

Deadline for nominations: September 16, 2016.

The specific job descriptions for each position are available online and the UEG statutes should be carefully considered during the definition of suitable candidates.

2 positions for Members on the National Societies Committee

Given UEG's focus on equality and the current composition of the National Societies Committee they will only consider female candidates for this round of elections during the meeting of the National Societies Forum at UEG Week Vienna 2016. Access the Call for Elections and Job Description.

Election of Chairs of the EUG Scientific and Public Affairs Committee

Following Article 11 of the UEG statutes, Chairs of the Committees are elected already one year before the term of their predecessor ends to allow a smooth handover of business. Chair Elects for these positions will thus be elected during the Meeting of Members (former General Assembly) on occasion of UEG Week Vienna 2016.

Press Release: Medics call for urgent improvements in the quality of endoscopy across Europe

Tuesday, 05 April 2016 08:36

(Vienna) Every year, tens of millions of individuals across Europe undergo endoscopic procedures to assist with the diagnosis and management of gastrointestinal diseases. However, significant variation in current endoscopy provision across Europe has been reported¹, with back-to-back colonoscopy studies demonstrating that a concerning 22% of all adenomas are missed and that a three-to-six fold variation in adenoma detection is present between endoscopists².

This inconsistent provision, coupled with improved first-line screening methods, has created a requirement to improve the quality of endoscopy services as endoscopy of a high quality have been shown to deliver superior health outcomes, better patient experience and fewer repeat procedures³.

United European Gastroenterology (UEG) and The European Society of Gastrointestinal Endoscopy (ESGE) have therefore published a joint paper which identifies a need for change and outlines the first phase of a series of recommendations for improvements in quality standards of endoscopy.

UEG endoscopy specialist Professor Thierry Ponchon, who is a member of the ESGE Quality Improvement Committee, welcomes the publication of new standards. "Endoscopy services throughout Europe are at a critical point at the current time. We must make improvements in the quality of service for our patients a major and immediate priority. Our aim is achieve high quality standards for endoscopy throughout Europe over the next two years and create a thriving community of endoscopy services for all."

Regional Commissioning Workshops

Monday, 21 March 2016 11:52

Your clinical team are invited to meet your commissioners at a regional interactive half-day workshop:

Achieve a Winning Business Case to Improve Outcomes in Gastroenterology & Hepatology Services – An Action Plan

BIRMINGHAM Friday 6th May 8.30am-12.40pm Chair Dr Rupert Ransford
At University of Birmingham, Hornton Grange, 53 Edgbaston Park Rd, Edgbaston B15 2RS (free onsite parking)

MANCHESTER Wednesday 18th May 8.30am-12.40pm Chair: Dr Yeng Ang
Venue TBC

LONDON Friday 20th May 9am-1.15pm Chair: Dr A Frank Muller At Broadway House, Tothill Street London SW1H 9NQ

EAST OF ENGLAND Thursday 12th May 5.30pm-8.10pm Chair Dr Andrew Douds
At Bedford Lodge, Bury Road, Newmarket, CB8 7BX

The BSG has arranged a series of interactive, multi-disciplinary half day workshops for you to help address the challenges many of us are facing in developing our Gastroenterology and Hepatology services. Successful developments seem to occur when Clinicians and the wider Clinical Team work with local Commissioners to agree plans and how they can be funded. Please find the programme and registration form above. The BSG has fully supported this workshop as it is considered to be very important in enabling the developments that we all need to improve the standard of care of our patients.

The objectives are to understand your commissioners' priorities, new NHS developments, identify your service challenges, how to redesign you care pathways and begin to develop a winning business case and action plan with your Commissioners and patients.


To ensure the workshops are truly helpful for you we are asking you to bring along your Clinical Teams (e.g. clinical and nurse leads, hospital business and service managers) and invite your local CCG and Specialised Commissioners so you can discuss the challenges, priorities and actions to redesign your services.

Please find attached a suggested template email for you to invite your local commissioners to join you at this half day workshop. You will also need to attach the workshop programme.


The series of workshops will culminate with a National Action Plan recommending the key actions for you and your commissioners to improve your services. This will be launched at the BSG Annual Conference on 23rd June 2016 and copies will be sent FREE to all delegates.

We do hope you will be able to join us at this important meeting; please complete the registration form at the end of the programme and return it FREEPOST to Medical Management Services (UK) Ltd, the workshop organisers or simply register at

We would also like to thank both Norgine Ltd and Takeda Ltd whose funding have made these meetings possible.

BSG Guidance on the Use of Biosimilar Infliximab CT-P13 in IBD

February 2016

Introduction: Dr AB Hawthorne, Chair BSG IBD Section Committee

The infliximab biosimilar CT-P13 (Remsima or Inflectra) received marketing authorisation in June 2013.The drug is now widely used in the treatment of inflammatory bowel disease. There is sufficient data from observational studies to show that safety and clinical efficacy of CT-P13 are comparable to the originator drug, with similar immunogenicity.


  1. Infliximab must be prescribed by brand name (ie Remicade, Remsima or Inflectra) and not by International Non-proprietary Name (INN).
  2. For patients starting infliximab: Remicade, Remsima or Inflectra can be prescribed, taking into account the evidence showing similar clinical effectiveness. There is evidence that monitoring of patients, including measurement of drug and anti-drug antibody levels, is no different for the biosimilar drugs compared to Remicade. The choice of preparation should take into account the cost of the drug and its administration.
  3. There is sufficient evidence to recommend that patients who are in a stable clinical response or remission on Remicade therapy can be switched to Remsima or Inflectra at the same dose and dose interval. This should be done after discussion with individual patients, with explanation of the reason for switching (which is usually on the grounds of benefit to the overall service by reduction in costs of the drug and its administration).
  4. Automatic substitution, (dispensing one medicine instead of another equivalent and interchangeable medicine at the pharmacy level without consulting the prescriber), is not appropriate.
  5. Pharmacovigilance is essential for any new biological medicine, and patients prescribed Remsima or Inflectra should be followed for safety, in a registry such as the UK National IBD Registry.

This document replaces the previous BSG guidance on Biosimilar drugs - IBD Section Statement on Biosimilar drugs (2014) (View here)

Page 3 of 8